JP2009544610A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544610A5 JP2009544610A5 JP2009520782A JP2009520782A JP2009544610A5 JP 2009544610 A5 JP2009544610 A5 JP 2009544610A5 JP 2009520782 A JP2009520782 A JP 2009520782A JP 2009520782 A JP2009520782 A JP 2009520782A JP 2009544610 A5 JP2009544610 A5 JP 2009544610A5
- Authority
- JP
- Japan
- Prior art keywords
- immunization
- drug
- regulatory
- concomitant medication
- drug according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000003053 immunization Effects 0.000 claims 26
- 238000002649 immunization Methods 0.000 claims 26
- 229940124301 concurrent medication Drugs 0.000 claims 11
- 229940079593 drug Drugs 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 239000002246 antineoplastic agent Substances 0.000 claims 7
- 210000003289 regulatory T cell Anatomy 0.000 claims 7
- 230000001235 sensitizing effect Effects 0.000 claims 7
- 229940000425 combination drug Drugs 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 229940127089 cytotoxic agent Drugs 0.000 claims 5
- 230000006698 induction Effects 0.000 claims 5
- 230000003915 cell function Effects 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 230000002163 immunogen Effects 0.000 claims 4
- 229960001438 immunostimulant agent Drugs 0.000 claims 4
- 239000003022 immunostimulating agent Substances 0.000 claims 4
- 230000003308 immunostimulating effect Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000003796 beauty Effects 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 229940044683 chemotherapy drug Drugs 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 210000004324 lymphatic system Anatomy 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108020000411 Toll-like receptor Proteins 0.000 claims 1
- 102000002689 Toll-like receptor Human genes 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011277 treatment modality Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83125606P | 2006-07-14 | 2006-07-14 | |
| US86333206P | 2006-10-27 | 2006-10-27 | |
| US11/879,078 US20080014211A1 (en) | 2006-07-14 | 2007-07-14 | Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic and therapeutic purposes |
| PCT/US2007/016075 WO2008008541A2 (en) | 2006-07-14 | 2007-07-14 | Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009544610A JP2009544610A (ja) | 2009-12-17 |
| JP2009544610A5 true JP2009544610A5 (enExample) | 2010-09-02 |
Family
ID=38922728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009520782A Withdrawn JP2009544610A (ja) | 2006-07-14 | 2007-07-14 | 予防又は治療目的のためにｍｈｃクラスｉ拘束エピトープに対する免疫応答を引き出し、増強し、保持する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080014211A1 (enExample) |
| EP (1) | EP2046344A2 (enExample) |
| JP (1) | JP2009544610A (enExample) |
| AU (1) | AU2007272785A1 (enExample) |
| CA (1) | CA2657771A1 (enExample) |
| MX (1) | MX2009000452A (enExample) |
| WO (1) | WO2008008541A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6977074B2 (en) | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| EP1838342A2 (en) * | 2004-12-29 | 2007-10-03 | Mannkind Corporation | Methods to bypass cd+4 cells in the induction of an immune response |
| CA2612516C (en) | 2005-06-17 | 2015-03-24 | Mannkind Corporation | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
| KR20080033271A (ko) * | 2005-06-17 | 2008-04-16 | 맨카인드 코포레이션 | 암종을 위한 다가 동반이행 및 증폭형 면역치료제 |
| JP5496669B2 (ja) * | 2006-09-01 | 2014-05-21 | ジェンティセル | リンパ除去化合物、および抗原配列を含みかつプロフェッショナル抗原提示細胞をターゲットとする分子を含んでなる、特異的ｃｔｌ応答を誘発する組成物 |
| WO2011050344A2 (en) | 2009-10-23 | 2011-04-28 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
| US20140187843A1 (en) * | 2011-04-20 | 2014-07-03 | Joseph Friedberg | Radioisotope-photodynamic therapy for cancer treatment |
| JP6574179B2 (ja) * | 2013-07-31 | 2019-09-11 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | エフェクターｔレグ細胞を同定するための方法及びキット |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037135A (en) * | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
| US5747271A (en) * | 1992-12-22 | 1998-05-05 | Ludwig Institute For Cancer Research | Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals |
| US5698396A (en) * | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| US6994851B1 (en) * | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
| US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| US20030138808A1 (en) * | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
| US6709844B1 (en) * | 2000-11-16 | 2004-03-23 | Mannkind Corporation | Avoidance of undesirable replication intermediates in plasmid propagation |
| US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
| DE60142615D1 (de) * | 2000-04-28 | 2010-09-02 | Mannkind Corp | Epitop-synchronisierung in antigen präsentierenden zellen |
| US6861234B1 (en) * | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
| US6753384B2 (en) * | 2000-07-14 | 2004-06-22 | Metabolix, Inc. | Polyurethanes obtained from hydroxyalkanoates and isocyanates |
| EP1372736A4 (en) * | 2001-03-07 | 2004-11-17 | Mannkind Corp | PREPARATIONS AGAINST CANCER FORMATION |
| WO2003008537A2 (en) * | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
| CN101024842A (zh) * | 2001-11-07 | 2007-08-29 | 曼康公司 | 编码靶相关抗原表位的表达载体及其设计方法 |
| CN1691964A (zh) * | 2002-09-06 | 2005-11-02 | 曼康公司 | 表位序列 |
| GB0221574D0 (en) * | 2002-09-17 | 2002-10-23 | Isis Innovation | Treatments |
| AU2003301021C1 (en) * | 2002-12-16 | 2010-02-18 | Globelmmune, Inc. | Yeast-based vaccines as immunotherapy |
| MXPA05013973A (es) * | 2003-06-17 | 2006-03-02 | Mannkind Corp | Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos. |
| ATE546153T1 (de) * | 2003-06-17 | 2012-03-15 | Mannkind Corp | Kombinationen von tumor-assoziierten antigenen zur behandlung von verschiedenen krebstypen |
| US20060159689A1 (en) * | 2004-06-17 | 2006-07-20 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| EP2332971B1 (en) * | 2004-06-17 | 2016-02-17 | MannKind Corporation | Epitope analogs |
| JP2008503494A (ja) * | 2004-06-17 | 2008-02-07 | マンカインド コーポレイション | 診断方法を治療方法と統合することによる免疫療法の効力改善 |
| US20060008468A1 (en) * | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| EP2351576A1 (en) * | 2004-12-29 | 2011-08-03 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
| KR101294290B1 (ko) * | 2004-12-29 | 2013-08-07 | 맨카인드 코포레이션 | 예방 또는 치료를 위해 제ｉ류 주조직 적합성복합체〔ｍｈｃ〕-제한 에피토프에 대한 면역 반응을 유발,향상 및 지속하는 방법 |
| AU2005321898B2 (en) * | 2004-12-29 | 2012-07-19 | Mannkind Corporation | Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines |
| EP1838342A2 (en) * | 2004-12-29 | 2007-10-03 | Mannkind Corporation | Methods to bypass cd+4 cells in the induction of an immune response |
| KR20080033271A (ko) * | 2005-06-17 | 2008-04-16 | 맨카인드 코포레이션 | 암종을 위한 다가 동반이행 및 증폭형 면역치료제 |
| CA2612516C (en) * | 2005-06-17 | 2015-03-24 | Mannkind Corporation | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
| US7511119B2 (en) * | 2005-06-17 | 2009-03-31 | Mannkind Corporation | PRAME peptide analogues |
| GB0519303D0 (en) * | 2005-09-21 | 2005-11-02 | Oxford Biomedica Ltd | Chemo-immunotherapy method |
-
2007
- 2007-07-14 US US11/879,078 patent/US20080014211A1/en not_active Abandoned
- 2007-07-14 MX MX2009000452A patent/MX2009000452A/es not_active Application Discontinuation
- 2007-07-14 EP EP07810479A patent/EP2046344A2/en not_active Withdrawn
- 2007-07-14 JP JP2009520782A patent/JP2009544610A/ja not_active Withdrawn
- 2007-07-14 WO PCT/US2007/016075 patent/WO2008008541A2/en not_active Ceased
- 2007-07-14 AU AU2007272785A patent/AU2007272785A1/en not_active Abandoned
- 2007-07-16 CA CA002657771A patent/CA2657771A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009544610A5 (enExample) | ||
| Zhao et al. | Amplified cancer immunotherapy of a surface-engineered antigenic microparticle vaccine by synergistically modulating tumor microenvironment | |
| Zhang et al. | Advancements of radiotherapy for recurrent head and neck cancer in modern era | |
| Garbe et al. | Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting | |
| Confino et al. | Inhibition of mouse breast adenocarcinoma growth by ablation with intratumoral alpha-irradiation combined with inhibitors of immunosuppression and CpG | |
| Wang et al. | BNCT for locally recurrent head and neck cancer: preliminary clinical experience from a phase I/II trial at Tsing Hua open-pool reactor | |
| JP2013536157A5 (enExample) | ||
| JP2010529026A5 (enExample) | ||
| JP2012067116A5 (enExample) | ||
| Gunderson et al. | Exploring optimal sequencing of radiation and immunotherapy combinations | |
| Domankevich et al. | RIG-1-like receptor activation synergizes with intratumoral alpha radiation to induce pancreatic tumor rejection, triple-negative breast metastases clearance, and antitumor immune memory in mice | |
| JP2006506441A5 (enExample) | ||
| NZ601677A (en) | Improved cancer therapy based on tumor associated antigens derived from cyclin d1 | |
| JP2011103891A5 (enExample) | ||
| Nadella et al. | Emerging neo adjuvants for harnessing therapeutic potential of M1 tumor associated macrophages (TAM) against solid tumors: Enusage of plasticity | |
| Bergman | Cancer immunotherapy | |
| JP2016526531A5 (enExample) | ||
| Soukup et al. | Radiation meets immunotherapy–a perfect match in the era of combination therapy? | |
| JP2019531293A5 (enExample) | ||
| CN103110939A (zh) | 诱导肿瘤特异性免疫的疫苗及其应用 | |
| Schneble et al. | Breast cancer immunotherapy | |
| Fujimoto et al. | Overcoming immunotherapy resistance and inducing abscopal effects with boron neutron immunotherapy (B‐NIT) | |
| Wang et al. | rWTC‐MBTA vaccine induces potent adaptive immune responses against glioblastomas via dynamic activation of dendritic cells | |
| Passelli et al. | Strategies for overcoming tumour resistance to immunotherapy: harnessing the power of radiation therapy | |
| Skalickova et al. | Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer |